Current Pharmaceutical Design

William A. Banks  
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108


Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery

Author(s): Latanya M. Scott, Harshani R. Lawrence, Said M. Sebti, Nicholas J. Lawrence and Jie Wu

Affiliation: Department of Molecular Oncology, SRB-3, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612.


Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome. Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes. While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase. In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed. Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.

Keywords: Protein tyrosine phosphatase inhibitor, Shp2, PTP1B, Cdc14, PRL-3, LMW-PTP, Cdc25, eya

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [1843 - 1862]
Pages: 20
DOI: 10.2174/138161210791209027
Price: $58